Belfast Health and Social Care Trust licensee HiberGene Diagnostics Ltd has raised €2m.
The company has received a syndicated investment comprising a €500,000 investment by the Bank of Ireland MedTech Accelerator Fund with the remainder of funds provided by Enterprise Ireland and private investors.
The company will use this round of funding to support the commercialisation of its first two rapid molecular tests for Meningococcal Meningitis and Group B Streptococcus, which were developed at the Royal Victoria Hospital in Belfast and to which it has secured licenses from Belfast HSC Trust.
HiberGene previously announced that it had secured a licence from Eiken Chemical Company, Japan, to the Loop Mediated Isothermal Amplification (LAMP) technology used in the tests.
Further information from Kernel Capital: www.kernel-capital.com/news/2015/feb02_15.html.